Filtering

Page: () 1 2 3
JCC: Volume 11, Issue 7, 2017Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Year: 2017
Source: JCC: Volume 11, Issue 7, 2017
Authors: Marcus Harbord, Rami Eliakim, Dominik Bettenworth, Konstantinos Karmiris, Konstantinos Katsanos, Uri Kopylov, Torsten Kucharzik, Tamás Molnár, Tim Raine, Shaji Sebastian, Helena Tavares de Sousa, Axel Dignass, Franck Carbonnel

The treatment strategy for ulcerative colitis [UC] is mainly based on the severity, distribution [proctitis, left-sided, extensive]1 and pattern of disease. The latter includes relapse frequency, disease course, response to previous medications, side effects of medication, and extra-intestinal manifestations. Age at onset, and disease duration are also important factors. It is important to distinguish patients with severe UC necessitating hospital admission from those with mild or moderately active disease who can be managed as outpatients. The best validated and most widely used index for identifying severe UC remains that of Truelove and Witts.2 Patients with bloody stool frequency ≥ 6/day and a tachycardia [> 90 min−1], or temperature > 37.8°C, or anaemia [haemoglobin < 10.5 g/dl], or an elevated erythrocyte sedimentation rate [ESR] [> 30 mm/h] have severe UC. Only one additional criterion in addition to the bloody stool frequency ≥ 6/day is needed to define a severe attack.3,4 In practice, a C-reactive protein [CRP] of 30 mg/l can be substituted for the ESR.

JCC, Volume 6, Issue 10, 2012Ulcerative Colitis (UC) Consensus Part 2 - Current management (2012)
Year: 2012
Source: JCC, Volume 6, Issue 10, 2012
Authors: Axel Dignass, Rami Eliakim, Fernando Magro, Christian Maaser, Yehuda Chowers, Karel Geboes, Gerassimos Mantzaris, Walter Reinisch, Jean-Frederic Colombel, Severine Vermeire, Simon Travis, James O. Lindsay, Gert Van Assche

Ulcerative colitis is a lifelong disease arising from an interaction between genetic and environmental factors, observed predominantly in the developed countries of the world. The precise aetiology is unknown and therefore medical therapy to cure the disease is not yet available. Within Europe there is a North–South gradient, but the incidence appears to have increased in Southern and Eastern countries in recent years.1,2 Patients may live with a considerable symptom burden despite medical treatment (66% describe interference with work and 73% with leisure activities3) in the hope that the aetiology of ulcerative colitis will shortly be revealed and a cure emerge. Although this is conceivable in the next decade, clinicians have to advise patients on the basis of information available today. Despite randomised trials there will always be many questions that can only be answered by the exercise of judgement and opinion. This leads to differences in practice between clinicians, which may be brought into sharp relief by differences in emphasis between countries.

JCC: Volume 7, Issue 1, 2013Ulcerative Colitis (UC) Consensus Part 3 - Special situations (2012)
Year: 2012
Source: JCC: Volume 7, Issue 1, 2013
Authors: Gert Van Assche, Axel Dignass, Bernd Bokemeyer, Silvio Danese, Paolo Gionchetti, Gabriele Moser, Laurent Beaugerie, Fernando Gomollón, Winfried Häuser, Klaus Herrlinger, Bas Oldenburg, Julian Panes, Francisco Portela, Gerhard Rogler, Jürgen Stein, Herbert Tilg, Simon Travis, James O. Lindsay
ECCO News Issue 1/2017Y-ECCO Literature Review: A microbial signature for Crohn's Disease
Year: 2017
Source: ECCO News Issue 1/2017
Authors: Clara Caenepeel
Files: 1
ECCO News Issue 1/2017Y-ECCO Literature Review: Drug safety and risk of adverse outcomes for pregnant patients with IBD
Year: 2017
Source: ECCO News Issue 1/2017
Authors: Emma Flanagan
Files: 1
ECCO News Issue 03/2016Y-ECCO Literature Review: Gene-microbiota interactions contribute to the pathogenesis of Inflammatory Bowel Disease
Year: 2016
Source: ECCO News Issue 03/2016
Authors: Floris Imhann
Files: 1
ECCO News Issue 4/2016Y-ECCO Literature Review: Gut and liver T-cells of common clonal origin in primary sclerosing cholangitis-inflammatory bowel disease
Year: 2016
Source: ECCO News Issue 4/2016
Authors: Anna Friederike Cordes
Files: 1
ECCO News Issue 02/2016Y-ECCO Literature Review: Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s Disease after ileocolonic resection
Year: 2016
Source: ECCO News Issue 02/2016
Authors: Paula Sousa
Files: 1
ECCO News Issue 4/2016Y-ECCO Literature Review: Interleukin 1β mediates intestinal inflammation in mice and patients with interleukin 10 receptor deficiency
Year: 2016
Source: ECCO News Issue 4/2016
Authors: Nurulamin Noor
Files: 1
ECCO News Issue 03/2016Y-ECCO Literature Review: Ozanimod induction and maintenance treatment for Ulcerative Colitis
Year: 2016
Source: ECCO News Issue 03/2016
Authors: Jonathan Segal
Files: 1
ECCO News Issue 02/2016Y-ECCO Literature Review: The safety of vedolizumab for Ulcerative Colitis and Crohn’s Disease
Year: 2016
Source: ECCO News Issue 02/2016
Authors: João Sabino
Files: 1
Page: () 1 2 3